LY4005130
LY4005130 is in Phase 2 for alopecia areata, developed by Eli Lilly.
A new Lilly molecule in alopecia areata, given intravenously, of undisclosed mechanism, in a placebo-controlled Phase 2 since April 2026.
- Developed by
- Eli Lilly
- Current phase
- Phase 2
- Mechanism
- Undisclosed
- Indications
- Alopecia areata
- Also known as
- LY-4005130
- Last public activity
- September 2026
- Copy last reviewed
- September 2026
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
The sponsor has not said how it is supposed to work.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
Lilly already sells baricitinib for severe alopecia areata in the US, EU and Japan; LY4005130 is a different molecule from the same company in the same indication. The trial is a randomised, double-blind proof of concept in adults with severe disease, recruiting since 14 April 2026 in seven countries, with the drug given intravenously; a parallel Phase 2 in non-segmental vitiligo started the same day. No target, drug class or molecule type has been published, and this row does not guess.
Development history
- Phase 2
First Phase 2 trial on record: NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company · n=60 · April 2026
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) — ClinicalTrials.gov
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo — ClinicalTrials.gov
- Study to investigate efficacy and safety of LY4005130 in adult participants with severe alopecia areata — study listing — Other, May 2026
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "LY4005130 — development record", hairpipeline.com/pipeline/ly4005130